NewAmsterdam Pharma Company N.V. announced the appointment of John W. Smither as an independent director to its Board of Directors. Mr. Smither will also serve as chair of the company's Audit Committee. Most recently, Mr. Smither served as the Chief Financial Officer at Arcutis Biotherapeutics, where he was responsible for all financial aspects of the company's business, including leading Arcutis' successful initial public offering and two capital raises.

Prior to joining Arcutis, Mr. Smither served as the CFO of Sienna Biopharmaceuticals from April 2018 until March 2019. He also served as interim CFO for Kite Pharma during its integration with Gilead. Mr. Smither has 15 years' experience as a practicing CPA (inactive), including time spent as an audit partner at Ernst & Young.

Mr. Smither has previously served on the Boards of several biopharmaceutical companies and currently serves as director at both eFFECTOR Therapeutics and Applied Molecular Transport. He holds a B.S. in Business Administration from California State University, Los Angeles.